<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

5 min read

Positive Growth in Q120: Infection Prevention Vascular Access Recap

By Susan Paquette on 7/2/20 10:15 AM

Q120 remained a bright spot showing positive growth with modest disruption from COVID-19 for the quarter.

For Q120, according to BioMedGPS’ SmartTRAK Financial Dashboard, the US Infection Prevention - Vascular Access Adjunct Products market was up +4. 4% YoY. The prevention of Hospital-Acquired Infections (HAIs) continues to drive measures and practices to reduce Central Line-Associated Bloodstream Infections (CLABSIs) and is creating demand for products that can address these issues. Numerous programs and educational tools are being developed to provide measures and strategies that assist healthcare providers in the prevention and reduction of infection in acute care and other settings.

Among the many topics covered in the comprehensive Q120 Infection Prevention: Vascular Access Adjunct Products Recap Market Recap* are:

Topics: Wound Care
Continue Reading
6 min read

Hemostats and Sealants Up Despite COVID-19: Q120 Market Report

By Doug Devens on 7/1/20 10:24 AM

The US market for Hemostats and Sealants grew +6.1% YoY in Q120, up from the pace of Q419 despite the late appearance of COVD-19 in the last few weeks of the quarter. Growth was slightly higher in the Hemostats market, with +6.8% growth driven by relative strength in thrombin hemostats.

As reported in SmartTRAK Financial Dashboard, the US Hemostats and Sealants market had a growth rate of +6.1% in Q120. Leading the way in Q120 was Baxter* with +11.6% YoY growth and continued strength from Tisseel* and Artiss* fibrin sealants. Becton Dickinson* (BD) also posted strong gains as its relaunched Progel* and continued its resurgence in Q120. However, all manufacturers predicted that second-quarter results would be much worse since the full effect of surgery deferrals would be felt for the entire quarter. Some manufacturers warned that revenues were reduced as much as...

Among the many topics covered in the comprehensive Q120 Hemostats and Sealants Market Recap* are:

Topics: Wound Care
Continue Reading
5 min read

Advanced Wound Care Posts Modest Gains Offset by China: Q120 Market Recap

By Susan Paquette on 6/22/20 11:22 AM

In Q120, the US and EU AWC markets experienced modest gains, offset by ROW (China) hit early in the quarter with COVID-19.

For Q120, according to BioMedGPS’ SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenues for Advanced Dressings, External Devices and Biologics was up +2.2% YoY. Many companies commented on the impact of COVID-19 on their business performance. Overall, the impact in Q120 was limited, as the pandemic hit in March in most countries, whereas Jan and Feb were more business as usual. All are expecting a more severe impact in Q220, and almost all companies have withdrawn their FY20 projections.

Among the many topics covered in the comprehensive Q120 Advanced Wound Care Market Recap* are:

Topics: Wound Care
Continue Reading
6 min read

The Week in Wound Care: New Studies, Products and COVID-19 Impacts

By Thomas Wallick on 6/8/20 7:37 PM

As the world begins to reopen from COVID-19, the wound care industry is making progress on new medical devices and studies. The following is a small sampling of Wound Care segment updates from the past week that were compiled, reviewed and posted in real-time by our SmartTRAK analysts, who are constantly monitoring the situation and sifting through the noise to present the most relevant news to our subscribers.
 
Alliance of Wound Care Stakeholders - CMS COVID-19 
  • The Alliance of Wound Care Stakeholders requested that CMS allow HOPDs and MDs to bill for furnishing dNPWT during the COVID-19 pandemic when providing wound assessment and instruction to patients in their home on the application of dNPWT via telehealth.
  • The Alliance of Wound Care Stakeholders submitted comments to CMS COVID-19 Public Health Emergency Interim Final Rule. The Alliance supported the Agency’s implementation of many policies while also pursuing clarification on several specific provisions.
Pressure Injury in China

A study of 1,806 nurses from 10 hospitals in China on nurses' knowledge, attitudes and behaviors for promoting PI-prevention found 41.7% had insufficient PI-prevention knowledge, 46.6% had negative PI-prevention attitudes, and 21.8% had poor PI-prevention behavior. J Clin Nurs

Improved Textured Breast Implants

Establishment Labs’ US Patent Application “TEXTURED SURFACES FOR BREAST IMPLANTS” was published, describing irregularly-textured breast implants with significantly improved cellular response over current textured implants. 20200170771

Continue Reading
12 min read

Unique Biomaterials Opportunity: An Interview with Michael Ziebell of trū Shrimp

By Susan Paquette on 5/27/20 12:44 PM

.SmartTRAK discusses a new biomaterials opportunity for medical devices with Michael Ziebell, President and CEO of trū Shrimp.

Shrimp is the most popular seafood in the US with an annual consumption of 1.6 billion pounds and 90% sourced outside the US. trū Shimp has developed a unique aquaculture for raising shrimp that allows production to occur anywhere in the US, even in Minnesota. Michael Ziebell explains the unique features of the process and its ability to produce a novel biomaterial that may be tailored to meet the needs of the medical device industry.

A transcript of SmartTRAK’s interview with Michael Ziebell is below. To listen to the audio interview, click on the video (10:39 minutes). The full transcript, with a link to download a PDF, is provided below.

Topics: Wound Care
Continue Reading
4 min read

Q419/FY19 Infection Prevention Recap: VA Adjunct Products Post Gains

By Susan Paquette on 4/24/20 12:39 PM

FY19 showed solid gains in all segments, up +4.1% YoY, as antimicrobial devices take the lead

The prevention of Hospital-Acquired Infections (HAIs) continues to drive measures and practices to reduce Central Line-Associated Bloodstream Infections (CLABSIs) and is creating demand for products that can address these issues. Numerous programs and educational tools are being developed to provide measures and strategies that assist healthcare providers in the prevention and reduction of infection in acute care and other settings.

According to BioMedGPS' SmartTRAK Financial Dashboard, the Q419 US VA Adjunct Products market saw a solid increase of +3.7% for the four segments: Dressings, Antimicrobial Devices, Antimicrobial IV Skin Preps and Mechanical Securement Devices.

Among the many topics including news, financial data, charts and company revenues, covered in the comprehensive Q419/FY19 Infection Prevention: Vascular Access Adjunct Products Market Recap*, are:

Topics: Wound Care
Continue Reading
3 min read

Q419/FY19 AWC Market Recap: Solid Growth and Acquisitions

By Susan Paquette on 4/20/20 9:00 AM

A year of solid growth and acquisitions for the WW AWC market, as 3M moves into the leading position.

For FY19, according to BioMedGPS’ SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenue for Advanced Dressings, External Devices and Biologics was up +4.7% YoY.

3M captured the number one position in the AWC space after completing the acquisition of Acelity and its KCI subsidiaries on October 11, 2019. According to SmartTRAK Financial Dashboard, in FY19, combined 3M and Acelity seized 22.7% of the market and generated +6.2% YoY growth. Revenue for Q419 was up +6.9% YoY, driven by ongoing strong performance in single-use negative pressure wound therapy and solid growth in Advanced Wound Dressings. 

Among the many topics, including news, financial data, charts and company revenues, covered in the comprehensive Q419/FY19 Advanced Wound Care Market Recap*,  are:

Topics: Wound Care
Continue Reading
3 min read

Q419/FY19 US Hemostats and Sealants Market Recap: Solid Growth

By Doug Devens on 4/10/20 10:18 AM

The US market for Hemostats and Sealants grew +5.8% YoY in Q419, comparable to its +6.2% growth in Q319, with continued strength in fibrin sealants and good growth in absorbable hemostats.

As reported in SmartTRAK Financial Dashboard, the US Hemostats and Sealants market maintained a solid growth rate of +5.8% in Q419 and grew +5.7% YoY. Leading the way in Q419 was Becton Dickinson (BD),  as its relaunch of Progel continued its resurgence. Baxter also posted strong gains.

Among the many topics covered in the comprehensive Q419/FY19 US Hemostats and Sealants Market Recap* are:

Topics: Wound Care
Continue Reading
4 min read

Q419/FY19 US Surgical Matrices Market Recap: Robust Growth

By Doug Devens on 3/27/20 9:49 AM

The US Surgical Matrices Market showed robust growth in Q419, improving on Q319. Breast matrices rebounded from its Q319 malaise, while hernia matrices grew YoY.

In Q419, the US Surgical Matrices Market grew +8.5% YoY, and was up +4.2% for FY19 according to BioMedGPS’ SmartTRAK Financial Dashboard. Allergan broke out of its  Alloderm supply constraints, and Becton Dickinson (BD) also did quite well.
  • Q419 Breast Matrices market found its groove again, up YoY. For FY19 Breast Matrices grew well, despite several weak quarters.
  • Q419 US Hernia Matrices market increased its growth, with the highest growth rate in biosynthetics and with both xenografts and allografts showing surprising strength. For the year, Hernia Matrices edged up.
  • Allergan beat its supply constraints and maintained its leadership of the Breast Matrices market, as Alloderm returned to the market in force. For the full year, Allergan slid due to those Alloderm supply problems.
  • BD maintained its No. 1 position in the Q419 Hernia Matrices market.

Among the many topics covered in the comprehensive Q419/FY19 US Surgical Matrices Market Recap* are:

Topics: Wound Care
Continue Reading
6 min read

Wound Care Payer Coverage: An Interview with Marcia Nusgart

By Susan Paquette on 3/5/20 9:00 AM

Marcia Nusgart, Executive Director, Alliance of Wound Care Stakeholders, discusses the upcoming Wound Care Evidence Summit and improving payer coverage in an interview with SmartTRAK.

In the market for wound care products, the success of any product is highly dependent on whether or not manufacturers are able to obtain a positive coverage determination from public and commercial payers. In the last several years, obtaining product reimbursement has been more challenging as payers are restricting coverage for a growing number of wound care products due to a lack of clarity surrounding clinical evidence.

So, what are payers looking for? What and how much clinical evidence do payers need to cover wound care products and procedures? How can manufacturers prepare scientific evidence to meet payer needs, improve coverage and achieve more uniform policies for treating wounds in all healthcare settings? To answer these questions and more, the Alliance of Wound Care Stakeholders is convening payers, regulators, researchers, manufacturers and wound care providers at its upcoming Wound Care Evidence Summit to be held April 1-2, 2020 in Washington, DC.

To find out about the Summit, improving payer coverage and opportunities for industry, SmartTRAK’s Susan Paquette interviewed Marcia Nusgart, Executive Director of the Alliance of Wound Care Stakeholders.

Topics: Wound Care
Continue Reading

    Recent Articles